Takeda provides updates on phase 1/2 clinical trials of novavax' and moderna's covid-19 vaccine candidates in japan

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) announced today that the first subject was dosed in its phase 1/2 immunogenicity and safety study of novavax' covid-19 vaccine candidate (tak-019) in japan. earlier this month, takeda completed enrollment in the company's phase 1/2 immunogenicity and safety study of moderna's covid-19 vaccine candidate (tak-919) in japan. “early in the pandemic, we made the decision to partner with other companies and lever
TAK Ratings Summary
TAK Quant Ranking